<DOC>
	<DOCNO>NCT00736970</DOCNO>
	<brief_summary>This clinical trial study use ridaforolimus metastatic breast cancer subject whose tumor show resistance trastuzumab ( herceptin ) . The goal study find subject treat ridaforolimus combination trastuzumab positive response treatment , treatment ridaforolimus combination trastuzumab prolongs survival .</brief_summary>
	<brief_title>Oral Deforolimus With Trastuzumab Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer ( 8669-009 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Female , 18 year age old Histologically confirm HER2positive metastatic breast cancer Trastuzumabresistance Measurable disease , accord RECIST guideline ECOG performance status less equal 1 Life expectancy great 3 month No prior treatment temsirolimus , everolimus , rapamycin , mTOR inhibitor At least 4 week must lapse prior investigational therapy , chemotherapy radiotherapy , first dose ridaforolimus Left ventricular ejection great equal 50 % Adequate cardiovascular function Adequate hematological , hepatic , renal function Serum cholesterol less equal 350 mg/dL triglyceride less equal 400 mg/dL Negative pregnancy test within 7 day prior first dose study drug must use approved contraceptive method screen 30 day last dose study drug Availability patient consent obtain archival tissue sample Signed informed consent Inadequate recovery prior surgical procedure undergone major surgery within 2 week trial entry Grade 1 Grade 2 hypersensitivity reaction prior trastuzumab therapy reaction prevent trastuzumab administration Grade 3 Grade 4 hypersensitivity reaction prior trastuzumab Symptomatic intrinsic lung disease extensive tumor involvement lung , result dyspnea rest Known allergy macrolide antibiotic Pregnant breastfeed Know history HIV Diagnosis brain metastasis leptomeningeal carcinomatosis within 3 month Other malignancy within past 3 year , except adequately treat carcinoma cervix basal squamous cell carcinoma skin Active infection require prescription intervention Newly diagnose poorly control Type 1 2 diabetes Other concurrent illness , Investigator 's judgment , would either compromise patient 's safety interfere evaluation safety study drug Concurrent treatment medication strongly induce inhibit cytochrome P450 . Any condition render patient unable fully understand provide inform consent and/or comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ridaforolimus</keyword>
	<keyword>deforolimus</keyword>
	<keyword>AP23573</keyword>
	<keyword>breast cancer</keyword>
</DOC>